Sulfocysteine Determination - Urine

Clinical Use

Use

The Sulfocysteine Determination test provides quantitative analysis of sulfocysteine in urine. Pathogenic variants in the SUOX gene are known to be associated with sulfocysteinuria, which is a neurological disorder characterized by progressive postnatal encephalopathy. This condition can lead to severe complications such as progressive microcephaly, muscle stiffness, spastic quadriplegia, and seizures over time. Additionally, elevated urine sulfocysteine levels can indicate molybdenum cofactor deficiency, which also leads to serious symptoms, including developmental delay and distinctive facial features. Recognizing these conditions early through testing can facilitate monitoring and management of the disorders.

Special Instructions

Indications for Testing include patients with a clinical or suspected diagnosis of isolated sulfite oxidase deficiency/sulfocysteinuria or molybdenum cofactor deficiency. This test may also be used to track and monitor treatment or therapy responses. Understanding the genetic inheritance is crucial, as both disorders are inherited in an autosomal recessive manner, necessitating two copies of a pathogenic variant for manifestation. Parents who are carriers have a 25% risk of having an affected child, signifying the importance of carrier screening.

Limitations

It is important to note that while elevated sulfocysteinuria levels can indicate specific metabolic disorders, not all cases of elevated levels will result in a positive diagnosis. The test results should be interpreted in conjunction with clinical findings and other laboratory tests. False positives may occur due to various physiological conditions or variations in individual metabolism. Carrier screening is also limited; negative results do not completely rule out the chance of having an affected child, especially in carrier couples.

Test Details